Abstract The PI3K/Akt/mTOR pathway regulates several normal cellular functions that are
also critical for tumorigenesis, including cellular proliferation, growth, survival and mobility.
Components of this pathway are frequently abnormal in a variety of tumors, making them an
attractive target for anti-cancer therapy. Inhibition of mTOR in patients with cancer became
more feasible after the development of rapamycin analogs with improved pharmacologic
properties. The promising activity of these agents in early clinical trials has led to the …